People who receive stem cell therapy within a week of their first heart attack have nearly a 60 per cent lower risk of developing heart failure years later
People who received an infusion of stem cells shortly after a heart attack were less likely to develop heart failure than those treated with standard care, according to the largest such trial to date. The finding provides some of the strongest evidence yet that stem cells can help the heart repair itself.
Paywalled story: Stem cell therapy lowers risk of heart failure after a heart attack (NewScientist)
Other:
Research Paper (open access):
Prevention of acute myocardial infarction induced heart failure by intracoronary infusion of mesenchymal stem cells: phase 3 randomised clinical trial (PREVENT-TAHA8)
Conclusions Intracoronary infusion of Wharton’s jelly derived mesenchymal stem cells significantly reduced the risk of incidence of heart failure, readmission to hospital for heart failure, and the composite endpoint of cardiovascular mortality and readmission to hospital for heart failure or myocardial infarction in patients after an acute myocardial infarction, suggesting that this technique may serve as a valuable adjunctive procedure after myocardial infarction to prevent the development of heart failure and reduce the risk of future adverse events.